دورية أكاديمية
Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.
| العنوان: | Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register. |
|---|---|
| المؤلفون: | Fagerli KM; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Kearsley-Fleet L; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK., Mercer LK; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK., Watson K; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK., Packham J; Institute of Applied Clinical Sciences, Keele, UK., Symmons DPM; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.; National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK., Hyrich KL; Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.; National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK. |
| المصدر: | Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2019 Jan 01; Vol. 58 (1), pp. 80-85. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN: 1462-0332 (Electronic) Linking ISSN: 14620324 NLM ISO Abbreviation: Rheumatology (Oxford) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford, UK : Avenel, N.J. : Oxford University Press ; Distributed by Mercury International, c1999- |
| مواضيع طبية MeSH: | Antirheumatic Agents/*adverse effects , Arthritis, Psoriatic/*mortality , Biological Products/*adverse effects , Neoplasms/*mortality , Tumor Necrosis Factor-alpha/*antagonists & inhibitors, Adult ; Aged ; Arthritis, Psoriatic/drug therapy ; Cause of Death ; Coronary Disease/chemically induced ; Coronary Disease/mortality ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Neoplasms/chemically induced ; Registries ; Skin Neoplasms/chemically induced ; Skin Neoplasms/mortality ; United Kingdom/epidemiology |
| مستخلص: | Objective: The aim of this study was to compare the incidence of cancer and all-cause and cause-specific mortality rates among a cohort of patients with severe PsA receiving TNF inhibitor (TNFi) with those of the general UK population. Methods: Cancers and deaths were identified from the national cancer and the national death registers in patients with PsA included in the British Society for Rheumatology Biologics Register from start of TNFi until 31 December 2012. Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) were calculated using published cancer and death rates for the general population. SIRs were calculated for both overall cancer risk and non-melanoma skin cancer. SMRs were calculated for (1) all-cause mortality, (2) death from malignancy and (3) death from circulatory disease. Gender-specific analyses were also performed. Results: Thirty-four cancers and 41 deaths among 709 patients were observed. The risk of malignancy overall was not increased (SIR 0.94; 95% CI: 0.65, 1.34). However, there was a significantly increased incidence of non-melanoma skin cancer (SIR 2.12; 95% CI: 1.19, 3.50). The all-cause mortality rate in our cohort was increased (SMR 1.56; CI: 1.12, 2.11). Death from malignancy was not increased, but death from coronary heart disease was increased (SMR 2.42; 95% CI: 1.11, 4.59). Conclusion: In our cohort of patients with severe PsA, the overall incidence of malignancy was similar to that of the general population, although the incidence of non-melanoma skin cancer was increased. All-cause mortality was significantly increased, in part due to excess of deaths attributed to coronary heart disease. |
| References: | J Rheumatol. 2016 Dec;43(12):2155-2161. (PMID: 27909142) Ann Rheum Dis. 2008 Mar;67(3):364-9. (PMID: 17644547) J Clin Rheumatol. 2016 Aug;22(5):241-7. (PMID: 26886439) Ann Rheum Dis. 2015 Feb;74(2):326-32. (PMID: 25351522) Arthritis Rheum. 2007 Aug;56(8):2708-14. (PMID: 17665458) JAMA Dermatol. 2016 Mar;152(3):282-90. (PMID: 26676102) Rheumatology (Oxford). 2017 Jun 1;56(6):907-911. (PMID: 28158384) Ann Rheum Dis. 2006 Oct;65(10):1373-8. (PMID: 16644783) Arthritis Res Ther. 2009;11(2):R52. (PMID: 19356232) J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:12-29. (PMID: 23845149) Arthritis Rheum. 2011 Feb;63(2):382-90. (PMID: 21279995) Rheumatology (Oxford). 2013 Jan;52(1):91-8. (PMID: 23238979) Rheumatology (Oxford). 2010 Apr;49(4):697-705. (PMID: 20056769) Ann Rheum Dis. 2017 Jan;76(1):105-111. (PMID: 27147709) Arthritis Rheum. 2010 Nov;62(11):3145-53. (PMID: 20662063) Ann Rheum Dis. 2014 Jan;73(1):149-53. (PMID: 23264338) |
| معلومات مُعتمدة: | 20380 United Kingdom ARC_ Arthritis Research UK |
| المشرفين على المادة: | 0 (Antirheumatic Agents) 0 (Biological Products) 0 (TNF protein, human) 0 (Tumor Necrosis Factor-alpha) |
| تواريخ الأحداث: | Date Created: 20180824 Date Completed: 20191023 Latest Revision: 20200309 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC6293477 |
| DOI: | 10.1093/rheumatology/key241 |
| PMID: | 30137485 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1462-0332 |
|---|---|
| DOI: | 10.1093/rheumatology/key241 |